相关实验视频
Updated: Jun 9, 2025

09:11
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
6.5K
氨酸脱乙酶抑制剂在细胞中具有较低的选择性,并且主要表现出非目标效应
Kiara E Bornes1, Marcus A Moody2, Thomas M Huckaba3
1Department of Chemistry, Xavier University of Louisiana, New Orleans, LA, USA.
FEBS open bio
|November 1, 2024
概括
氨酸脱乙酶 (KDAC) 抑制剂显示出显著的脱效应,而不是预期的KDAC抑制. 基因失活揭示了真正的生物学作用,为KDAC6抑制剂提出了新的治疗策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 氨酸脱乙酶 (KDACs) 调节氨酸乙化,这是一个关键的翻译后修饰,涉及到许多细胞过程.
- KDACs的失调与各种疾病有关,使它们成为潜在的治疗点.
- 选择性KDAC抑制是理解个体KDAC功能和开发向疗法的必要条件.
研究的目的:
- 为了比较KDAC抑制剂的生物效应与KDAC6和KDAC8.8的遗传失活化.
- 为了评估常用的KDAC抑制剂的特异性和脱效应,Tubastatin A和PCI-34051.
- 澄清KDAC6和KDAC8在细胞过程和疾病模型中的作用.
主要方法:
- 使用了带有基因失活KDAC6或KDAC8酶的HT1080细胞.
- 给细胞注射了Tubastatin A和PCI-34051,并将其与基因失活效应进行了比较.
- 进行基因表达分析以确定抑制剂的非目标效应.
- 在KDAC6/KDAC8.8基因失活后,在异种移植模型中评估瘤形成.
主要成果:
- 对KDACs的遗传失活化导致了比抑制剂治疗更明显的脱甲基化缺陷.
- 图巴斯丁A和PCI-34051都表现出广泛的和重叠的非目标效应,即使在低剂量下也是如此.
- 图巴斯丁A增加了基因素乙化,而基因KDAC6/KDAC8不活化则没有.
- 基因失活KDAC6,但没有KDAC8,损害瘤形成,与之前的抑制剂研究相矛盾.
结论:
- 大多数归因于KDAC抑制剂的生物效应可能是由于非标结合.
- 基因无活化为研究个体KDAC功能提供了更准确的方法.
- 开发具有高度特异性的KDAC6抑制剂,模仿基因失活是一种有前途的治疗策略.
相关概念视频
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.7K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.7K
Antiasthma Drugs: Leukotriene Modifiers
246
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
246
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
551
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
551
Dose-Response Relationship: Selectivity and Specificity
6.5K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.5K
Skeletal Muscle Relaxants: Adverse Effects
337
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
337
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
526
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
526

